Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B. Margolskee A, et al. Among authors: hoft c. Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2. Eur J Pharm Sci. 2017. PMID: 27816631
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B. Darwich AS, et al. Among authors: hoft c. Eur J Pharm Sci. 2017 Jan 1;96:626-642. doi: 10.1016/j.ejps.2016.09.037. Epub 2016 Sep 28. Eur J Pharm Sci. 2017. PMID: 27693299
Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Dallas S, Salphati L, Gomez-Zepeda D, Wanek T, Chen L, Chu X, Kunta J, Mezler M, Menet MC, Chasseigneaux S, Declèves X, Langer O, Pierre E, DiLoreto K, Hoft C, Laplanche L, Pang J, Pereira T, Andonian C, Simic D, Rode A, Yabut J, Zhang X, Scheer N. Dallas S, et al. Among authors: hoft c. Mol Pharmacol. 2016 May;89(5):492-504. doi: 10.1124/mol.115.102079. Epub 2016 Feb 18. Mol Pharmacol. 2016. PMID: 26893303
Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.
Amberg W, Lange UEW, Ochse M, Pohlki F, Behl B, Relo AL, Hornberger W, Hoft C, Mezler M, Sydor J, Wang Y, Zhao H, Brewer JT, Dietrich J, Li H, Akritopoulou-Zanze I, Lao Y, Hannick SM, Ku YY, Vasudevan A. Amberg W, et al. Among authors: hoft c. J Med Chem. 2018 Sep 13;61(17):7503-7524. doi: 10.1021/acs.jmedchem.8b00300. Epub 2018 Aug 27. J Med Chem. 2018. PMID: 30080045
De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.
Wang Y, Zhao H, Brewer JT, Li H, Lao Y, Amberg W, Behl B, Akritopoulou-Zanze I, Dietrich J, Lange UEW, Pohlki F, Hoft C, Hornberger W, Djuric SW, Sydor J, Mezler M, Relo AL, Vasudevan A. Wang Y, et al. Among authors: hoft c. J Med Chem. 2018 Sep 13;61(17):7486-7502. doi: 10.1021/acs.jmedchem.8b00295. Epub 2018 Jul 17. J Med Chem. 2018. PMID: 29969029
Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain.
Morawe MP, Liao F, Amberg W, van Bergeijk J, Chang R, Gulino M, Hamilton C, Hoft C, Lumpkin C, Mastis B, McGlame E, Nuber J, Plaas C, Ravikumar B, Roy K, Schanzenbächer M, Tierno J, Lakics V, Dellovade T, Townsend M. Morawe MP, et al. Among authors: hoft c. Eur J Pharmacol. 2022 Nov 5;934:175301. doi: 10.1016/j.ejphar.2022.175301. Epub 2022 Sep 30. Eur J Pharmacol. 2022. PMID: 36191631 Free article.
Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates.
Greenberg EF, Voorbach MJ, Smith A, Reuter DR, Zhuang Y, Wang JQ, Wooten DW, Asque E, Hu M, Hoft C, Duggan R, Townsend M, Orsi K, Dalecki K, Amberg W, Duggan L, Knight H, Spina JS, He Y, Marsh K, Zhao V, Ybarra S, Mollon J, Fang Y, Vasanthakumar A, Westmoreland S, Droescher M, Finnema SJ, Florian H. Greenberg EF, et al. Among authors: hoft c. Heliyon. 2024 Aug 17;10(16):e36483. doi: 10.1016/j.heliyon.2024.e36483. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39253182 Free PMC article.
The PLA2G6 gene in early-onset Parkinson's disease.
Kauther KM, Höft C, Rissling I, Oertel WH, Möller JC. Kauther KM, et al. Among authors: hoft c. Mov Disord. 2011 Nov;26(13):2415-7. doi: 10.1002/mds.23851. Epub 2011 Aug 2. Mov Disord. 2011. PMID: 21812034
12 results